We found that the expression values of ANXA1 were significantly higher in GBM patients than in those with normal brain and lower-grade gliomas (WHO II and WHO III) in Dataset 1 (p < 5e-5, Figure 1A). This evidence concerns the gene ANXA1 and glioma.